Answer
Mogamulizumab (Poteligeo) is contraindicated in patients with hypersensitivity to mogamulizumab or any excipient listed in section 6.1.
Sources for this answer
- Poteligeo 4 mg/mL, Concentrate for Solution for InfusionKyowa Kirin Ltd · emc · SmPC §4.3 Contraindications · Version 9Document updated
Sources checked